Goldman Sachs Sticks to Its Hold Rating for GlaxoSmithKline (GSK)
Goldman Sachs analyst Rajan Sharma maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £16.90.
GlaxoSmithKline (GSK) Receives a Hold from Jefferies
Jefferies analyst Peter Welford maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) today. The company’s shares opened today at ...
GSK's drug combo shown to cut risk of death by 42% in type of blood cancer
British drugmaker GSK said on Monday its experimental cancer drug Blenrep in combination with other treatments reduced the ...
Cancellation of kids’ asthma medication continues to cause turmoil for Mass. families
Massachusetts families are still struggling to find alternatives almost a year after GlaxoSmithKline canceled a widely ...
WJET Erie on MSN2mon
Drugmaker to settle nearly 80,000 Zantac lawsuits for up to $2.2 billion
UK-based pharmaceutical giant GSK, or GlaxoSmithKline, has announced that it has agreed to settle nearly 80,000 state-level ...
pharmaphorum2d
FDA clears GSK's Priorix, first new MMR vaccine in 50 years
With vaccine hesitancy leading to a rise in measles cases, the FDA's approval of GlaxoSmithKline's venerable vaccine Priorix for sale in the US looks timely. Priorix was first launched in Europe ...
Wall Street Journal7d
GlaxoSmithKline Pakistan Ltd.
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...